Rheumatoid Arthritis Research Studies
The Division of Rheumatology strives to understand more about rheumatoid arthritis (RA) through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
| Study Name/IRB#/PI | Brief Description | Basic Eligibility Criteria | Contact |
Interdisciplinary Joint Biology Program for Rheumatic and Orthopedic Diseases 20-1908 Larry Moreland, MD | The goal of the University of Colorado Interdisciplinary Joint Biology Program is to employ cutting edge science and technology to advance the research of inflammatory, degenerative and musculoskeletal joint diseases. | Individuals with RA, SpA, PsA, AS, OA or any other form of inflammatory arthritis with active disease in their elbow, wrist, hand joints, knee, ankle or shoulder and are willing to undergo a synovial biopsy at that site or individuals who are having an orthopedic surgery and are willing to donate their tissues that would normally be discarded | 303-724-7541 Jennifer.Seifert@CUanschutz.edu Or visit https://medschool.cuanschutz.edu/cuijbp |
Platelet Function in RA 20-2318 Pavel
Davizon-Castillo, MD; PI | A study to learn more about platelet function in people with RA pre Anti-TNF and post Anti-TNF. Visit consists of consent and 2 additional tubes drawn during regular clinic visit. No additional questionnaires collected. |
| 303-724-7510 Marie.Feser@CUAnschutz.edu |
CPIRA-2 20-2619 Kevin Deane, MD | A study designed to learn more about pain in early Rheumatoid Arthritis. It’s a 1 year study with 3 visits (baseline, 3 months, 1 year). | Individuals with Rheumatoid Arthritis for less than 6 months may be eligible | 303-724-7510 Marie.Feser@CUAnschutz.edu |
MINERAL; Microbiome and Neutrophil associated factors in Rheumatoid Arthritis and Autoimmune-related Interstitial Lung Disease 20-2769 Melissa Griffith, MD | An observational study to investigate the causes of chronic lung disease in rheumatoid arthritis and other autoimmune diseases | 1. At least 18 years old 2. Falls under one of the following criteria: a. Diagnosis of scleroderma b. Diagnosis of idiopathic pulmonary fibrosis (IPF) or interstitial pneumonia with autoimmune features (IPAF) c. Diagnosis of RA with associated interstitial lung disease d. Diagnosis of RA with previous lung abnormalities seen on lung scan | 303-724-0071
|
ALTRA 19-1150Kevin Deane, MD | To learn about the immune system and microbiome in individuals at risk for developing RA | Individuals with a positive blood test (anti-CCP antibody) or their close relatives (parents, siblings, children) | 303-724-8330 Or email rastudies@cuanschutz.edu Or visit website: www.altraproject.org |
| SPARO Sputum Studies of Anti-Citrullinated Protein Antibodies (ACPA) and Rheumatoid Arthritis (RA) Origins [SPARO] 20-0206 Kristen Demoruelle, MD, PhD | An observational study to investigate the lung as a potential site where rheumatoid arthritis (RA) is developed. | At least 18 years old Falls under one of the following criteria: 1) has a parent, sibling, or child who is diagnosed with RA 2) has a clinically confirmed RA diagnosis 3) no personal or family history of RA | 303-724-0071
|
SAIL-RA 21-4765 PI: Kevin Deane MD, PhD | An observational research study to better understand why some people with rheumatoid arthritis (RA) develop a related condition called RA-associated interstitial lung disease (RA-ILD). | Inclusion criteria
Exclusion criteria
| 303-724-7510
|
RA-SCREEN 22-1580 PI: M. Kristen Demoruelle, MD, PhD | An observational study designed to identify individuals who might be at risk for developing RA via RA-associated autoantibody screening in participants. | Participants in this project can be: Confirmed or suspected FDRs (first degree relatives) of someone with RA, healthy controls (HC), or individuals with self- or family-reported RA. Adults between 18 and 100 years are eligible to participate. Once screening is completed, the participant will be grouped into one of the following groups: At-Risk, RA (diagnosed), or HC. | 303-724-0071 |
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length. A visit to determine an individuals eligibility may be required. A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.